OBA-PHARMA ApS: Financial statements 2023
CVR: 19995607
Source: annual report 2023, Danish Business Authority
01/10/2022 – 30/09/2023
OBA-PHARMA ApS (CVR 19995607) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 2,852,775 and a net result of DKK 2,073,440 compared with DKK 752,443 the year before. That is an increase of 174% compared with the year before. Equity in the 2023 report amounted to DKK 2,244,768. The solvency ratio was 19.4%.
- Gross Profit
- DKK 2,852,775
- Profit/Loss
- DKK 2,073,440
- Equity
- DKK 2,244,768
- Total Assets
- DKK 11,593,574
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 2.9 mio. | 2.1 mio. | 2.2 mio. | 0 |
| 2022 | - | 1 mio. | 752 t. | 1.9 mio. | 0 |
| 2021 | - | 1.3 mio. | 1 mio. | 2.2 mio. | 0 |
| 2020 | - | 1.1 mio. | 865 t. | 1.2 mio. | 0 |
| 2019 | - | 2.3 mio. | 1.8 mio. | 2.3 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
OBA-PHARMA ApS has published its annual report for 2022. Gross profit came to DKK 1,041,316, and the net result was DKK 752,443.
About OBA-PHARMA ApS
OBA-PHARMA ApS is a Danish company of the type Anpartsselskab based in København K, founded in 1997. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named PBH 25.376 ApS. The management consists of Malene Dybdahl Birch. The company is owned by LEV-VEL ApS and NLDB Holding ApS. The company has 0 employees (2000). In 2024, the company reported a gross profit of DKK 3,402,201 and a net result of DKK 2,670,973 compared with DKK 2,073,440 the year before. Equity in the 2024 report amounted to DKK 674,251.